Can AI help create “smart borders” between countries?
A refugee in Uganda’s Oruchinga settlement uses an iris scan to claim food assistance.
In 2016, border patrols in Greece, Latvia and Hungary received a prototype for an AI-powered lie detector to help screen asylum seekers. The detector, called iBorderCtrl, was funded by the European Commission in hopes to eventually mitigate refugee crises like the one sparked by the Syrian civil war a year prior.
iBorderCtrl, which analyzes micro expressions in the face, received but one slice of the Commission’s €34.9 billion border control and migration management budget. Still in development is the more ambitious EuMigraTool, a predictive AI system that will process internet news and social media posts to estimate not only the number of migrants heading for a particular country, but also the “risks of tensions between migrants and EU citizens.”
Both iBorderCtrl and EuMigraTool are part of a broader trend: the growing digitization of migration-related technologies. Outside of the EU, in refugee camps in Jordan, the United Nations introduced iris scanning software to distribute humanitarian aid, including food and medicine. And in the United States, Customs and Border Protection has attempted to automate its services through an app called CBP One, which both travelers and asylum seekers can use to apply for I-94 forms, the arrival-departure record cards for people who are not U.S. citizens or permanent residents.
According to Koen Leurs, professor of gender, media and migration studies at Utrecht University in the Netherlands, we have arrived at a point where migration management has become so reliant on digital technology that the former can no longer be studied in isolation from the latter. Investigating this reliance for his new book, Digital Migration, Leurs came to the conclusion that applications like those mentioned above are more often than not a double-edged sword, presenting both benefits and drawbacks.
There has been “a huge acceleration” in the way digital technologies “dehumanize people,” says Koen Leurs, professor of gender, media and migration studies at Utrecht University in the Netherlands. Governments treat asylum seekers as test subjects for new inventions, all along the borders of the developed world.
On the one hand, digital technology can make migration management more efficient and less labor intensive, enabling countries to process larger numbers of people in a time when global movement is on the rise due to globalization and political instability. Leurs also discovered that informal knowledge networks such as Informed Immigrant, an online resource that connects migrants to social workers and community organizers, have positively impacted the lives of their users. The same, Leurs notes, is true of platforms like Twitter, Facebook, and WhatsApp, all of which migrants use to stay in touch with each other as well as their families back home. “The emotional support you receive through social media is something we all came to appreciate during the COVID pandemic,” Leurs says. “For refugees, this had already been common knowledge for years.”
On the flipside, automatization of migration management – particularly through the use of AI – has spawned extensive criticism from human rights activists. Sharing their sentiment, Leurs attests that many so-called innovations are making life harder for migrants, not easier. He also says there has been “a huge acceleration” in the way digital technologies “dehumanize people,” and that governments treat asylum seekers as test subjects for new inventions, all along the borders of the developed world.
In Jordan, for example, refugees had to scan their irises in order to collect aid, prompting the question of whether such measures are ethical. Speaking to Reuters, Petra Molnar, a fellow at Harvard University’s Berkman Klein Center for Internet and Society, said that she was troubled by the fact that this experiment was done on marginalized people. “The refugees are guinea pigs,” she said. “Imagine what would happen at your local grocery store if all of a sudden iris scanning became a thing,” she pointed out. “People would be up in arms. But somehow it is OK to do it in a refugee camp.”
Artificial intelligence programs have been scrutinized for their unreliability, their complex processing, thwarted by the race and gender biases picked up from training data. In 2019, a female reporter from The Intercept tested iBorderCtrl and, despite answering all questions truthfully, was accused by the machine of lying four out of 16 times. Had she been waiting at checkpoint on the Greek or Latvian border, she would have been flagged for additional screening – a measure that could jeopardize her chance of entry. Because of its biases, and the negative press that this attracted, iBorderCtrl did not move past its test phase.
While facial recognition caused problems on the European border, it was helpful in Ukraine, where programs like those developed by software company Clearview AI are used to spot Russian spies, identify dead soldiers, and check movement in and out of war zones.
In April 2021, not long after iBorderCtrl was shut down, the European Commission proposed the world’s first-ever legal framework for AI regulation: the Artificial Intelligence Act. The act, which is still being developed, promises to prevent potentially “harmful” AI practices from being used in migration management. In the most recent draft, approved by the European Parliament’s Liberties and Internal Market committees, the ban included emotion recognition systems (like iBorderCtrl), predictive policing systems (like EUMigraTool), and biometric categorization systems (like iris scanners). The act also stipulates that AI must be subject to strict oversight and accountability measures.
While some worry the AI Act is not comprehensive enough, others wonder if it is in fact going too far. Indeed, many proponents of machine learning argue that, by placing a categorical ban on certain systems, governments will thwart the development of potentially useful technology. While facial recognition caused problems on the European border, it was helpful in Ukraine, where programs like those developed by software company Clearview AI are used to spot Russian spies, identify dead soldiers, and check movement in and out of war zones.
Instead of flat-out banning AI, why not strive to make it more reliable? “One of the most compelling arguments against AI is that it is inherently biased,” says Vera Raposo, an assistant professor of law at NOVA University in Lisbon specializing in digital law. “In truth, AI itself is not biased; it becomes biased due to human influence. It seems that complete eradication of biases is unattainable, but mitigation is possible. We can strive to reduce biases by employing more comprehensive and unbiased data in AI training and encompassing a wider range of individuals. We can also work on developing less biased algorithms, although this is challenging given that coders, being human, inherently possess biases of their own.”
AI is most effective when it enhances human performance rather than replacing it.
Accessibility is another obstacle that needs to be overcome. Leurs points out that, in migration management, AI often functions as a “black box” because the migration officers operating it are unable to comprehend its complex decision-making process and thus unable to scrutinize its results. One solution to this problem is to have law enforcement work closely with AI experts. Alternatively, machine learning could be limited to gathering and summarizing information, leaving evaluation of that information to actual people.
Raposo agrees AI is most effective when it enhances human performance rather than replacing it. On the topic of transparency, she does note that making an AI that is both sophisticated and easy to understand is a little bit like having your cake and eating it too. “In numerous domains,” she explains, “we might need to accept a reduced level of explainability in exchange for a high degree of accuracy (assuming we cannot have both).” Using healthcare as an analogy, she adds that “some medications work in ways not fully understood by either doctors or pharma companies, yet persist due to demonstrated efficacy in clinical trials.”
Leurs believes digital technologies used in migration management can be improved through a push for more conscientious research. “Technology is a poison and a medicine for that poison,” he argues, which is why new tech should be developed with its potential applications in mind. “Ethics has become a major concern in recent years. Increasingly, and particularly in the study of forced migration, researchers are posing critical questions like ‘what happens with the data that is gathered?’ and ‘who will this harm?’” In some cases, Leurs thinks, that last question may need to be reversed: we should be thinking about how we can actively disarm oppressive structures. “After all, our work should align with the interests of the communities it is going to affect.”
Gene Transfer Leads to Longer Life and Healthspan
In August, a study provided the first proof-of-principle that genetic material transferred from one species to another can increase both longevity and healthspan in the recipient animal.
The naked mole rat won’t win any beauty contests, but it could possibly win in the talent category. Its superpower: fighting the aging process to live several times longer than other animals its size, in a state of youthful vigor.
It’s believed that naked mole rats experience all the normal processes of wear and tear over their lifespan, but that they’re exceptionally good at repairing the damage from oxygen free radicals and the DNA errors that accumulate over time. Even though they possess genes that make them vulnerable to cancer, they rarely develop the disease, or any other age-related disease, for that matter. Naked mole rats are known to live for over 40 years without any signs of aging, whereas mice live on average about two years and are highly prone to cancer.
Now, these remarkable animals may be able to share their superpower with other species. In August, a study provided what may be the first proof-of-principle that genetic material transferred from one species can increase both longevity and healthspan in a recipient animal.
There are several theories to explain the naked mole rat’s longevity, but the one explored in the study, published in Nature, is based on the abundance of large-molecule high-molecular mass hyaluronic acid (HMM-HA).
A small molecule version of hyaluronic acid is commonly added to skin moisturizers and cosmetics that are marketed as ways to keep skin youthful, but this version, just applied to the skin, won’t have a dramatic anti-aging effect. The naked mole rat has an abundance of the much-larger molecule, HMM-HA, in the chemical-rich solution between cells throughout its body. But does the HMM-HA actually govern the extraordinary longevity and healthspan of the naked mole rat?
To answer this question, Dr. Vera Gorbunova, a professor of biology and oncology at the University of Rochester, and her team created a mouse model containing the naked mole rat gene hyaluronic acid synthase 2, or nmrHas2. It turned out that the mice receiving this gene during their early developmental stage also expressed HMM-HA.
The researchers found that the effects of the HMM-HA molecule in the mice were marked and diverse, exceeding the expectations of the study’s co-authors. High-molecular mass hyaluronic acid was more abundant in kidneys, muscles and other organs of the Has2 mice compared to control mice.
In addition, the altered mice had a much lower incidence of cancer. Seventy percent of the control mice eventually developed cancer, compared to only 57 percent of the altered mice, even after several techniques were used to induce the disease. The biggest difference occurred in the oldest mice, where the cancer incidence for the Has2 mice and the controls was 47 percent and 83 percent, respectively.
With regard to longevity, Has2 males increased their lifespan by more than 16 percent and the females added 9 percent. “Somehow the effect is much more pronounced in male mice, and we don’t have a perfect answer as to why,” says Dr. Gorbunova. Another improvement was in the healthspan of the altered mice: the number of years they spent in a state of relative youth. There’s a frailty index for mice, which includes body weight, mobility, grip strength, vision and hearing, in addition to overall conditions such as the health of the coat and body temperature. The Has2 mice scored lower in frailty than the controls by all measures. They also performed better in tests of locomotion and coordination, and in bone density.
Gorbunova’s results show that a gene artificially transferred from one species can have a beneficial effect on another species for longevity, something that had never been demonstrated before. This finding is “quite spectacular,” said Steven Austad, a biologist at the University of Alabama at Birmingham, who was not involved in the study.
Just as in lifespan, the effects in various organs and systems varied between the sexes, a common occurrence in longevity research, according to Austad, who authored the book Methuselah’s Zoo and specializes in the biological differences between species. “We have ten drugs that we can give to mice to make them live longer,” he says, “and all of them work better in one sex than in the other.” This suggests that more attention needs to be paid to the different effects of anti-aging strategies between the sexes, as well as gender differences in healthspan.
According to the study authors, the HMM-HA molecule delivered these benefits by reducing inflammation and senescence (cell dysfunction and death). The molecule also caused a variety of other benefits, including an upregulation of genes involved in the function of mitochondria, the powerhouses of the cells. These mechanisms are implicated in the aging process, and in human disease. In humans, virtually all noncommunicable diseases entail an acceleration of the aging process.
So, would the gene that creates HMM-HA have similar benefits for longevity in humans? “We think about these questions a lot,” Gorbunova says. “It’s been done by injections in certain patients, but it has a local effect in the treatment of organs affected by disease,” which could offer some benefits, she added.
“Mice are very short-lived and cancer-prone, and the effects are small,” says Steven Austad, a biologist at the University of Alabama at Birmingham. “But they did live longer and stay healthy longer, which is remarkable.”
As for a gene therapy to introduce the nmrHas2 gene into humans to obtain a global result, she’s skeptical because of the complexity involved. Gorbunova notes that there are potential dangers in introducing an animal gene into humans, such as immune responses or allergic reactions.
Austad is equally cautious about a gene therapy. “What this study says is that you can take something a species does well and transfer at least some of that into a new species. It opens up the way, but you may need to transfer six or eight or ten genes into a human” to get the large effect desired. Humans are much more complex and contain many more genes than mice, and all systems in a biological organism are intricately connected. One naked mole rat gene may not make a big difference when it interacts with human genes, metabolism and physiology.
Still, Austad thinks the possibilities are tantalizing. “Mice are very short-lived and cancer-prone, and the effects are small,” he says. “But they did live longer and stay healthy longer, which is remarkable.”
As for further research, says Austad, “The first place to look is the skin” to see if the nmrHas2 gene and the HMM-HA it produces can reduce the chance of cancer. Austad added that it would be straightforward to use the gene to try to prevent cancer in skin cells in a dish to see if it prevents cancer. It would not be hard to do. “We don’t know of any downsides to hyaluronic acid in skin, because it’s already used in skin products, and you could look at this fairly quickly.”
“Aging mechanisms evolved over a long time,” says Gorbunova, “so in aging there are multiple mechanisms working together that affect each other.” All of these processes could play a part and almost certainly differ from one species to the next.
“HMM-HA molecules are large, but we’re now looking for a small-molecule drug that would slow it’s breakdown,” she says. “And we’re looking for inhibitors, now being tested in mice, that would hinder the breakdown of hyaluronic acid.” Gorbunova has found a natural, plant-based product that acts as an inhibitor and could potentially be taken as a supplement. Ultimately, though, she thinks that drug development will be the safest and most effective approach to delivering HMM-HA for anti-aging.
A new study provides key insights in what causes Alzheimer's: a breakdown in the brain’s system for clearing waste.
In recent years, researchers of Alzheimer’s have made progress in figuring out the complex factors that lead to the disease. Yet, the root cause, or causes, of Alzheimer’s are still pretty much a mystery.
In fact, many people get Alzheimer’s even though they lack the gene variant we know can play a role in the disease. This is a critical knowledge gap for research to address because the vast majority of Alzheimer’s patients don’t have this variant.
A new study provides key insights into what’s causing the disease. The research, published in Nature Communications, points to a breakdown over time in the brain’s system for clearing waste, an issue that seems to happen in some people as they get older.
Michael Glickman, a biologist at Technion – Israel Institute of Technology, helped lead this research. I asked him to tell me about his approach to studying how this breakdown occurs in the brain, and how he tested a treatment that has potential to fix the problem at its earliest stages.
Dr. Michael Glickman is internationally renowned for his research on the ubiquitin-proteasome system (UPS), the brain's system for clearing the waste that is involved in diseases such as Huntington's, Alzheimer's, and Parkinson's. He is the head of the Lab for Protein Characterization in the Faculty of Biology at the Technion – Israel Institute of Technology. In the lab, Michael and his team focus on protein recycling and the ubiquitin-proteasome system, which protects against serious diseases like Alzheimer’s, Parkinson’s, cystic fibrosis, and diabetes. After earning his PhD at the University of California at Berkeley in 1994, Michael joined the Technion as a Senior Lecturer in 1998 and has served as a full professor since 2009.
Dr. Michael Glickman